CN106421523B - A kind of Chinese medicine compound prescription for treating gout - Google Patents
A kind of Chinese medicine compound prescription for treating gout Download PDFInfo
- Publication number
- CN106421523B CN106421523B CN201610960451.9A CN201610960451A CN106421523B CN 106421523 B CN106421523 B CN 106421523B CN 201610960451 A CN201610960451 A CN 201610960451A CN 106421523 B CN106421523 B CN 106421523B
- Authority
- CN
- China
- Prior art keywords
- compound
- chinese medicine
- patient
- effect
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to traditional Chinese medicine fields, are related to a kind of Chinese medicine compound prescription for treating gout.The component and weight proportion of the compound are as follows: 1 part of smilax, 1 part of Ramulus euonymi, raw 1 part of the seed of jog's tears, 1 part of paniculate swallowwort.The present invention is significant to the therapeutic effect of hyperuricemia and acute gouty arthritis, and without serious toxic side effect.Result in clinical application statistics and animal experiment study show that the patent of invention can be relieved hyperuricemia and urarthritis bring is ailing, and can significantly reduce the serum uric acid level of patient and rat, and without apparent toxic side effect.The effect that the patent of invention compound has is good, it is cheap, the advantages that Small side effects, meet most simple three basic demand of the patient for idealization treatment gout drug, the effect of patient's slight illness is relieved possessed by the patented invention compound, mitigate patient's bring side effect due to medication, while mitigating the financial burden of patient's medication.
Description
Technical field
The present invention relates to a kind of compound of Chinese herbal medicine special diseases to belong to especially for the good efficacy for the treatment of gout
Field of traditional Chinese medicine technology.
Background technique
Gout is crystal correlation arthropathy caused by a kind of monosodium urate mineralization, is arranged with purine metabolic disturbance or uric acid
The hyperuricemia let out caused by reducing is directly related.Gout be long-term disorders of purine metabolism and (or) underexcretion, blood urine
Acid increases one group of clinical syndrome for causing tissue damage, and hyperuricemia is the most important biochemical basis of gout.Gout includes
Acute gouty arthritis and chronic gout stone disease, can concurrent renal lesions, severe one may occur in which destruction of joint, kidney function energy loss
Evil, is often accompanied by high fat of blood, high blood pressure, diabetes, artery sclerosis and coronary heart disease etc., and disease incidence is in increase trend year by year.Bitterly
Wind and hyperuricemia have become the common disease of middle-aging male.In recent years, disease incidence is fallen ill year in the trend that rises year by year
Age presentation becomes younger, and brings huge burden to society, and close with the generation of the diseases such as hypertension, hyperlipidemia, diabetes
Cut phase is closed, and the early sign of identification metabolic syndrome is had become.At present, for gout and hyperuricemia conventional therapy still with
Based on Western medicine, colchicin, non-steroid anti-inflammatory drug, Benzbromarone, probenecid, allopurinol etc., these drugs are usually selected
Achieve the purpose that alleviation or treatment gout and hyperuricemia, but more and more clinical observation discoveries with different effect links
They all have certain toxic side effect, the adverse reactions such as Chang Yinqi nausea,vomiting,diarrhea, spasmodic colic.Such as colchicum
Alkali is once listed in the choice drug for the treatment of urarthritis acute attack, due to its therapeutic dose and ten split-phase of toxic dose
Closely, it is easy to happen poisoning, and adverse reaction is more, there is nausea,vomiting,diarrhea, bone marrow suppression, necrosis of liver cells and nervous system poison
Property, oligozoospermia, alopecia and Down's syndrome etc. cause gastrointestinal symptom, muscle, peripheral neuropathy, bone marrow suppression；It is not fast
Purine alcohol can cause hepatosis, the adverse reactions such as alpastic anemia allergic angiitis；Probenecid can cause molten
Hemolytic hemolytic anemia, anaphylactic shock, nephrotic syndrome etc.；Benzene smells Ma Long (narcaricin, benzene cumarin) and causes serious liver function energy barrier
Hinder.Therefore, drug therapy and new drug development increasingly attract people's attention, find more effective and toxic side effect is lower
Drug has become current task urgently to be resolved.In recent years, both at home and abroad for the pathogenesis of gout, clinical symptoms and its concurrent
The therapeutic agent of disease etc. has carried out a large amount of research, including the research to Chinese medicine, Chinese patent drug, currently, traditional Chinese medicine prevention is high
Uricacidemia has few side effects, is easily received and the advantages such as entirety curative effect ideal.Results of animal show single medicinal material or
Chinese medicine compound prescription can preferably reduce hyperuricemia model animal uric acid level [1].But there are still many for Chinese medicine treatment gout not
Foot place: the effect of Chinese medicine is multiple target point, therefore the synthesis of Chinese medicine influence factor multi-level to urarthritis, many-sided
It is still necessary to further study for regulation；Research at present mostly uses local joint symptoms simulation caused by exogenous Monosodium urate crystallization (MSU)
Model, be different from the urarthritis that the mankind are formed by dysbolism, therefore to the effect and effect of anti-gout drugs
The evaluation of mechanism is still inaccurate [2]；There is the effective component of chinese medicine of definite curative effect to be difficult to enter the Chinese Traditional Herbs Drug Clinical Testing stage, mostly
Number only stays in exploration and animal experiment stage to drug effect, and how these Basic Research Results are really transformed into clinic and answer
With the stage, there are problems, and the effective component just found, lack in terms of basic research systemic [3].Currently, opening refined
Et al. in the clinical observation of compound smilax granule therapy hyperuricemia find compound smilax particle can effectively reduce
Patients with Hyperuricemia serum uric acid level, and late result and safety are good [4].Turbid soup drops in Hu Xuguang et al. discovery coix lacryma-jobi to be pressed down
Acute rat paw edema caused by antidiuresis hydrochlorate reduces serum uric acid and prostaglandin E2 (PGE2) level, improves rat ankle
Synovial tissue of joint's inflammation [5].Modern studies have found that: semen coicis extract has significant ground analgesic and anti-inflammatory effects, can significantly press down
A variety of arthritis and capillary permeability are made, also can obviously reduce the amount of the PGE2 in inflammatory tissue, clinical report contains the heart of a lotus seed
The prescription of the seed of jog's tears is used for subacute and chronic rheumatic arthritis, [6] curative for effect.It is dry that Guo Shuyun etc. gives smilax water extract
Prognosis discovery, smilax can reduce hyperuricemia model mice serum uric acid (UA) level and serum xanthin oxydase
(XOD) active, thus it is speculated that smilax may reduce blood UA by inhibiting activity, the enhancing antioxidant ability of organism of XOD, play pair
The protective effect [7] of kidney., to the more target therapeutic agents of Future Development, weight will be had by preventing and treating gout and hyperuricemia for this
Want meaning.
Bibliography:
1.Wang HQ.Traditional Chinese and Western medicine research overview
Of hyperuricemia [J] .J NEW CHIN Med (new Chinese medicine), 2012,44 (4): 120-122.
2. the Study on mechanism of Li Ronghua, Nie Hui, Liu Youzhang Gouty Arthritis Treated by Chinese Drugs are in progress in the Liaoning [J]
Cure magazine, 2010,37 (7): 1398-1400.
3.Wang HQ, Zhan J, Wang XB.et al. effective component of chinese medicine treats hyperuricemia advances of Basic Research
[J].Chin J Pharmacol Toxicol,2015,29(3):471-476.
4 refined, Sun Weifeng, Hou Yan, and 40 randomized controlled clinicals of compound smilax granule therapy hyperuricemia is waited to see
Examine [J] .2016,1 (57): 41-45.
5. Hu Xuguang, Wen Ya, Dai Wangqiang wait coix lacryma-jobi to drop influence of the turbid soup to rat acute urarthritis model
[J] Chinese patent drug, 2014,36 (8): 1742-1744.
6. Gao Lan, Zhang Zhongyi, Zhang Li, experimental study [J] the Tianjin College of Traditional Chinese Medicine for waiting Yiyiren Decoction easing pain and diminishing inflammation to act on
Journal, 2004,23 (2): 62-64.
7. Guo Shuyun, Zhang Wei, the smilax water extract such as a kind of jade is to hyperuricemia model mice serum uric acid and glycerol three
Influence [J] China Dispensary of ester, cholesterol, 2011,22 (47): 4439-4440.
Summary of the invention
In order to which in the case where specific treatment hyperuricemia and acute gouty arthritis, reduction takes drugs bring
Side effect reduces the cost for the treatment of hyperuricemia and acute gouty arthritis.The present invention provides a kind of gouts for the treatment of
Traditional Chinese compound medicine, the drug efficiently solve the above problem of the existing technology.The effect that the patent of invention compound has
The advantages that fruit is good, cheap, Small side effects meets patient for most simple three base of idealization treatment gout drug
This requirement is relieved the effect of patient's slight illness possessed by the patented invention compound, mitigate patient's bring due to medication
Side effect, while mitigating the financial burden of patient's medication.
It is of the present invention treatment gout Chinese medicine compound prescription, component and weight are matched are as follows: 1 part of smilax, 1 part of Ramulus euonymi,
Raw 1 part of the seed of jog's tears, 1 part of paniculate swallowwort.
It specifically, is smilax 30g as the prescription proportion of single secondary Chinese medicine compound prescription, Ramulus euonymi 30g, raw seed of jog's tears 30g, Xu
Long minister in ancient times 30g.
The decoction of Chinese medicine compound prescription of the invention the preparation method comprises the following steps:
Decoction crude drug amount is smilax 30g, Ramulus euonymi 30g, and raw seed of jog's tears 30g, paniculate swallowwort 30g are put into 1.5L medicine decocting tank,
1L water is added, impregnates 1-2h, is boiled by fire in 2000W grades on electromagnetic oven, water is transferred to 500W continuation and is boiled about 1h, phase slightly after opening
Between with long chopsticks turn over medicine 3-5 times.After cooked, soup is filtered out with multilayer gauze, cooling is spare.
The Chinese medicine compound prescription, from it is clinical it is generous in simplify.Through many years clinical empirical summary and zoopery, it was demonstrated that really
Effective one group of best flavour of a drug, optimum proportioning simplify compound.Clinical use is experience have shown that this can significant reduction of patient clinic
Symptom.In addition, by rat experiment in vivo it was found that the water decoction of the compound can be relieved the arthroncus feelings of rat
Condition.And it is detected by instrument, the party can be substantially reduced the serum uric acid level of disease rat, and be in certain concentration dependant
Property.Moreover, generous compared to Chinese medicine, the water decoction side effect for taking the compound is less, compared to the treatment of Western medicine, the compound
The side effect of water decoction almost can be ignored.In conclusion the invention compound has following advantages:
1. the invention Chinese medicine compound prescription can be substantially reduced the serum uric acid level of rat, middle and high concentration compound group Chinese medicine effect compares
Obviously, hence it is evident that be better than colchicin group.
The 2 invention Chinese medicine compound prescriptions play apparent detumescence effect for the joint of suffering from of gouty model mouse, wherein in it is highly concentrated
It is close to spend dosage group detumescence effect, and in close proximity to colchicin group.Prove that the compound can be obviously improved facing for patient
Bed symptom.
3. the invention Chinese medicine compound prescription has an apparent inhibiting effect to the relevant inflammatory factor of urarthritis, especially in
Dosage group Chinese medicine compound prescription has apparent inhibiting effect for multiple inflammatory factors.
4. the invention Chinese medicine compound prescription does not find apparent liver kidney toxic side effect after taking experiment for a long time.
5. compared to treatment gout common Western medicine, the compound it is low in cost.
Detailed description of the invention
Fig. 1 patent of invention compound and big compound and other with flavour of a drug difference proportion compatibility compound effect compared with.
Effect (Fig. 2A) of Fig. 2 patent of invention compound to the blood uric acid of high lithemia blood trouble animal model rat；The hair
Bright patent compound acts on (Fig. 2 B) to the blood uric acid of acute gouty arthritis animal model rat.
Fig. 3 is compared with model group, swollen joint of the patented invention Chinese medicine compound prescription to acute gouty arthritis in rats
Swollen degree has apparent reduction to act on, and can effectively inhibit inflammatory reaction, mitigate the swelling situation (Fig. 3 A, B) in joint.
Every group of loading map and QAR-INF-1 of the fluorescence signal figure of Fig. 4 .QAR-INF-1.
Fig. 5 is calculated by fluorescence analysis software, patent of invention compound inflammatory factor IFN- relevant to gout
The inflammatory factors such as γ, IL-1 β, IL-2, IL-4, IL-13, TNF-α significantly inhibit.
Fig. 6 directly detects the patent of invention compound to the relevant inflammation of gout by the fluorescence thermal imaging of Raybiotech technology
The influence of inflammation factor IFN-γ, IL-1 β, IL-2, IL-4, IL-13, TNF-α, IL-1 α, IL-10, IL-6, MCP-1 etc..Fig. 7
Testing result of the invention compound for renal function index of correlation, the index including creatinine and urea nitrogen.
Fig. 8 invention compound shows liver, heart, spleen, kidney, thymus gland, phallic toxicity detection, HE dyeing
Show, without apparent toxic side effect.
Specific embodiment
1. the drug needed
Colchicin (positive control drug) (specification: 0.5mg, producer: Banna Pharmacy Industry Co., Ltd., Xishuangbanna, it is raw
Produce lot number: 150208)
Physiological saline (NS) (specification: 250ml, producer: Kelun Pharm Ind Co., Ltd., Sichuan)
Sodium urate crystal (MSU) (specification: 15mg, producer: sigma, article No.: U2875)
Adenine (Adenine) (specification: 25g, producer: sigma, article No.: A8626)
Oxonic Acid sylvite (Oxonic acid potassium salt) (specification: 25g, producer: sigma, article No.:
156124)
Sodium carboxymethylcellulose (Sodium carboxymethyl cellulose) (specification: 100g, producer: sigma,
Article No.: 419273)
Customizing high yeast feed, (specification: 2kg, producer: Jiangsu Province cooperates with medical bioengineering Co., Ltd, mass fraction
0.1) Chinese medicine:
Smilax (specification: 1kg, producer: Anhui Hui Long prepared slices of Chinese crude drugs Co., Ltd, product batch number: 20140326,
The place of production: Guangxi)
Ramulus euonymi (specification: 1kg, producer: Anhui Hui Long prepared slices of Chinese crude drugs Co., Ltd, product batch number: 20150321,
The place of production: Zhejiang)
The life seed of jog's tears (specification: 1kg, producer: Tian Ling prepared slices of Chinese crude drugs Co., Ltd, Suzhou City, product batch number:
150319010, the place of production: Jiangsu)
Paniculate swallowwort (specification: 1kg, producer: Anhui Hui Long prepared slices of Chinese crude drugs Co., Ltd, product batch number: 20141224,
The place of production: Shandong)
2. the preparation and concentration of Chinese medicine compound prescription decoction
(1) it prepares:
Compound A: decoction crude drug amount is smilax 30g, Ramulus euonymi 30g, and raw seed of jog's tears 30g, paniculate swallowwort 30g are put into 1.5L and decoct
In medicinal cupping, 1L water is added, impregnates 1-2h, is boiled by fire in 2000W grades on electromagnetic oven, water is transferred to 500W continuation and is boiled slightly after opening
Moon 1h, medicine during which is turned over 3-5 times with long chopsticks.After cooked, soup is filtered out with multilayer gauze, cooling is spare.(patient takes, most
Whole soup in two times, warmly takes sooner or later)
(2) filtered Chinese medicine soup is concentrated with spiral evaporimeter, and final medical fluid concentration containing crude drug amount is 1g/ml,
It is stand-by to be put into refrigerator.(zoopery needs this step)
(3) big Compound B: semen coicis 30g, paniculate swallowwort 30g, Ramulus euonymi 30g, smilax 30g, radix achyranthis bidentatae are prepared according to the above method
10g, root of Chinese clematis 15g, Cortex Phellodendri 10g, rhizoma atractylodis 10g, radix glycyrrhizae preparata 3g, Cortex Eucommiae 10g, herba taxilli 10g, Rhizoma Chuanxiong 10g.
(4) control is prepared simultaneously
Compound C: smilax 30g, Ramulus euonymi 15g, raw seed of jog's tears 30g, paniculate swallowwort 15g；
Compound D: smilax 15g, Ramulus euonymi 30g, raw seed of jog's tears 15g, paniculate swallowwort 30g；
Compound E: semen coicis 15g, paniculate swallowwort 30g, Ramulus euonymi 15g, smilax 30g.
3. the foundation of animal model
Animal: Wistar rat (male)
3.1 uric acid Salt treatment acute gouty arthritis models
(1) preparation of sodium urate crystals lotion weighs 10g sodium urate crystals, and measurement 100mL physiological saline is stand-by, will claim
Good sodium urate crystals slowly incorporate in the physiological saline of 100mL, form the suspension of sodium urate crystal (MSU) 100g/L.
(2) after adaptable fed, the ankle-joint chamber injection prepared sodium urate crystals of 0.2ml are outstanding after Rat Right when modeling
Turbid.(MSU suspension is injected into ankle-joint chamber on the inside of 45 degree of direction insertion shin bone tendons by Rat Right lateral joint back side)
(3) carry out model evaluation after 1h and two hour after injecting (inflammatory reactions such as redness occurs in arthroncus)
3.2 hyperuricemia rat model
(1) high yeast feed customization is in biotech firm
(2) it is stand-by to weigh 10g carboxymethyl cellulose powder for the preparation of sodium carboxymethylcellulose emulsion.1L is measured with graduated cylinder
Physiological saline is as in large beaker.It is heated to 60 DEG C in constant temperature blender with magnetic force, is slowly sprinkled into load weighted carboxylic while stirring
Sodium carboxymethylcellulose pyce.Until being completely dissolved stand-by in the uniform suspension of 10g/L.(note: above step is complete in super-clean bench
At)
(3) it is stand-by to weigh 20g Oteracil Potassium powder for the preparation of Oteracil Potassium solution.Same above-mentioned steps (1), by 20g oxygen piperazine
Sour potassium powder slowly incorporates in the sodium carboxymethylcellulose suspension that 750mL is prepared, and the suspension for being configured to 30g/L is spare.
(note: above step is completed in super-clean bench)
(4) preparation of adenine solution, weighing adenine powder 10g is stand-by, measures 1L physiology ultrapure water, slowly by powder
It is dissolved into 1L ultrapure water, the adenine solution for being configured to 10g/L is spare.
(6) the high yeast feed of the feeding rats customization of modeling group, while giving adenine 100mg/ (kg.d) point morning and evening
Stomach-filling, while giving Oteracil Potassium suspension 150mg/ (kg.d) subcutaneous injection twice, every minor tick 12h.
(7) daily timing tail vein takes blood, and full automatic biochemical apparatus detects serum uric acid level, continues the high level view of maintenance in three days
For modeling success.
4. rat oral gavage dosage
(1) rat day dosage converts referring to clinical patient Standard dose, Chinese medicine raw drug content (smilax in single compound
30g, Ramulus euonymi 30g, raw seed of jog's tears 30g, paniculate swallowwort 30g) amount to 120g.The daily dosage of the patient of weight 60kg is 120g raw
Medicine content is finally 2g/kg.So finally determining that rat medication contains crude drug amount is low dose group (5g/kg.d), middle dose group
(10g/kg.d), high dose group (20g/kg.d), other compound doses are converted into same raw drug content dosage and use.
5. rat grouping and respective handling
Negative control group (control, wait the stomach-filling of dosage ultrapure water)
Compound A group (compound A, middle dosage)
Compound B group (Compound B, middle dosage)
Compound C group (compound C, middle dosage)
Compound D group (compound D, middle dosage)
Compound E group (compound E, middle dosage)
6. rat grouping and respective handling
Negative control group (control, wait the stomach-filling of dosage ultrapure water)
+ 0g/ days dosage groups of model group (model group waits the stomach-filling of dosage ultrapure water)
+ 1g/ days dosage groups (low dose group) of model group
+ 2g/ days dosage groups (middle dose group) of model group
+ 4g/ days dosage groups (high dose group) of model group
Model group+the dosage of colchicin 0.06mg/ days group (western medicine group)
7. rat is handled
The processing of 6.1 acute gouty arthritis group rats
(1) start to be administered after modeling success, after successive administration 5 days, each group rat anesthesia, abdominal aortic blood fills respectively
It is neutralized in yellow head heparin tube into 1.5EP pipe.
(2) cut open and kill rat, win the liver of rat, kidney, spleen, thymus gland, genitals etc. be placed in liquid nitrogen freeze it is standby
With.
(3) Rat Right posterior joint is cut, is cut with ophthalmologic operation, synovial tissue is cut, is placed in spare in liquid nitrogen.
The processing of 6.2 hyperuricemia group rats
(1) start to be administered after determining modeling success, after successive administration 10 days, each group rat anesthesia, abdominal aortic blood, point
Not Zhuan Jin 1.5EP pipe neutralize in yellow head heparin tube.
(2) cut open and kill rat, win the liver of rat, kidney, spleen, thymus gland, genitals etc. be placed in liquid nitrogen freeze it is standby
With.8. later period sample process
(1) whole blood in 1.5mL EP pipe, carries out whole blood centrifugation immediately, and 3000rpm, 15min extract upper serum freezing
It is spare.
(2) blood in yellow head heparin tube is analyzed with full automatic biochemical apparatus, detects serum uric acid level, creatinine, urea nitrogen
Etc. indexs.
(3) make where reason (IL-1 β, IL-1 α, TNF-α, IL-2, IL-4, IL-6, IL-10, IL- after rat blood serum separation
13, MCP-1, IFNg) ELISA
9. data are analyzed
Data analysis is carried out with spss16.0.
10. experimental result
Patent of invention compound Compound A and big compound Compound B and other answered with flavour of a drug difference proportion compatibility
Square Compound C, Compound D and Compound E effect compare, the results show that the patent of invention compound effect is answered with big
Fang Xiaoguo is similar, no significant difference.Economically consider to be better than big compound.The compound compatibility ratio and other ratios
Discovery is compared, which is substantially better than other proportion compatibilities, and difference is statistically significant.Therefore final confirmation, changes
The best proportion compatibility of patent of invention compound is 1:1:1:1, as a result as shown in FIG. 1A and 1B.The patent of invention compound urinates height
Acidemia card animal model rat has the function of apparent blood uric acid (Fig. 2A).The patent of invention compound closes acute gout
Saving scorching animal model rat equally has the function of apparent blood uric acid (Fig. 2 B).Compared with model group, in the patented invention
Medicine compound has apparent reduction to act on the arthroncus degree of acute gouty arthritis in rats, can effectively inhibit scorching
Disease reaction, mitigates the swelling situation (Fig. 3 A, B) in joint.Experimental rat is carried out at sample using Raybiotech technology fluorescence
Reason, every group of loading map and QAR-INF-1 of the fluorescence signal figure of QAR-INF-1 is as shown in Figure 4 A, as can be seen from the figure should
Patent of invention compound significantly inhibits as shown in Figure 4 B the relevant inflammatory factor of part gout.Pass through fluorescence analysis
Software is calculated, the patent of invention compound to the relevant inflammatory factor IFN-γ of gout, IL-1 β, IL-2, IL-4, IL-13,
The inflammatory factors such as TNF-α significantly inhibit, as a result as shown in Figure 5.By Raybiotech technology fluorescence thermal imaging,
Directly detect the patent of invention compound to the relevant inflammatory factor IFN-γ of gout, IL-1 β, IL-2, IL-4, IL-13, TNF-α,
The influence of IL-1 α, IL-10, IL-6, MCP-1 etc..The patent of invention compound is to the relevant inflammatory factor IFN-γ of gout, IL-1
The inflammatory factors such as β, IL-2, IL-4, IL-13, TNF-α significantly inhibit, as a result as shown in Fig. 6 thermal map.The invention
The great advantage of patent Chinese medicine compound prescription is exactly effective, less toxic side effect.The detection of the invention compound for renal function index of correlation
The results show that the compound does not have apparent toxic side effect for renal function, hyperuricemia and acute can be effectively reduced instead
The raising of slight creatinine and urea nitrogen caused by urarthritis.As a result as shown in Figure 7.Detection for toxic side effect,
HE has dyed liver, kidney, spleen, thymus gland, heart, genitals of experimental rat etc., does not as a result find the patent of invention compound
There is apparent organ injury, as a result as shown in Figure 8.
In summary: (1) the patent of invention Chinese medicine compound prescription can be substantially reduced hyperuricemia and acute gouty arthritis
The serum uric acid level of group rat, middle and high concentration compound group Chinese medicine effect is obvious, is better than colchicin group.
(2) the patent of invention Chinese medicine compound prescription plays apparent detumescence effect for the joint of gouty model mouse, wherein in
High concentration dosage group detumescence effect is close, and in close proximity to colchicin group.
(3) the patent of invention Chinese medicine compound prescription has apparent inhibiting effect to the relevant inflammatory factor of urarthritis, especially
It is middle dose group Chinese medicine compound prescription, has apparent inhibiting effect for multiple inflammatory factors.
(4) the patent of invention Chinese medicine compound prescription is taken in short term, does not occur apparent hepatorenal damage.
Claims (1)
1. a kind of Chinese medicine compound prescription for treating gout, which is characterized in that be made of component below and weight proportion: 1 part of smilax,
1 part of Ramulus euonymi, raw 1 part and 1 part of paniculate swallowwort of the seed of jog's tears.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610960451.9A CN106421523B (en) | 2016-10-28 | 2016-10-28 | A kind of Chinese medicine compound prescription for treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610960451.9A CN106421523B (en) | 2016-10-28 | 2016-10-28 | A kind of Chinese medicine compound prescription for treating gout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106421523A CN106421523A (en) | 2017-02-22 |
| CN106421523B true CN106421523B (en) | 2019-08-30 |
Family
ID=58179754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610960451.9A Active CN106421523B (en) | 2016-10-28 | 2016-10-28 | A kind of Chinese medicine compound prescription for treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106421523B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108451904B (en) * | 2018-05-21 | 2021-02-09 | 中国农业科学院农产品加工研究所 | Potassium oxonate stable suspension and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940672B (en) * | 2010-08-30 | 2011-11-09 | 昆明肾脏病研究所 | Medicament for curing gout and preparation method thereof |
| CN103100006A (en) * | 2013-01-30 | 2013-05-15 | 无限极（中国）有限公司 | Chinese herbal medicine composition with uric acid reducing function |
| CN103127428A (en) * | 2013-03-27 | 2013-06-05 | 谢银芳 | Chinese patent drug for treatment of gouty arthritis |
| CN104524419A (en) * | 2015-01-16 | 2015-04-22 | 邓运明 | Traditional Chinese medicine preparation for treating gout |
-
2016
- 2016-10-28 CN CN201610960451.9A patent/CN106421523B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout;L.D. Kong等;《Journal of Ethnopharmacology》;20001231(第73期);第199-207页 * |
| Study on the correlation between constituents detected in serum from Rhizoma Smilacis Glabraeand the reduction of uric acid levels in hyperuricemia;WenAi Xu等;《Journal of Ethnopharmacology》;20131231(第150期);第747-754页 * |
| 复方土茯苓颗粒治疗高尿酸血症患者疗效分析;王天等;《华南国防医学杂志》;20121231(第2期);第128-130、133页 * |
| 薏仁降浊汤对大鼠急性痛风性关节炎模型的影响;胡旭光等;《中成药》;20141231(第8期);第1742-1744页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106421523A (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102920743B (en) | The application of spirulina in the anti-hyperuricemia of preparation and anti-gout drugs or health food | |
| CN109674958A (en) | A kind of Chinese medicine composition and its preparation method and application with anti-trioxypurine | |
| CN112791160A (en) | Uric acid-reducing anti-inflammatory analgesic medicinal and edible traditional Chinese medicine composition and preparation method thereof | |
| CN108186877A (en) | For the Chinese medicine composition of syndrome of blood stasis due to qi deficiency myocardial infarction secondary prevention | |
| CN106421523B (en) | A kind of Chinese medicine compound prescription for treating gout | |
| CN115887568B (en) | Traditional Chinese medicine composition for treating liver injury caused by lipid metabolism disorder and preparation method thereof | |
| CN101978982B (en) | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury | |
| CN104042720A (en) | Traditional Chinese medicine for preventing and treating diabetes with depression and application of traditional Chinese medicine | |
| CN104721467B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
| CN101554406B (en) | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN103211996B (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN110051817A (en) | A kind of Chinese traditional medicine composition and its application reducing uric acid | |
| US20220047658A1 (en) | Tcm addition and subtraction prescription used prevention/treatment of metabolic syndrome and complications | |
| Cho et al. | The evaluation of the body weight lowering effects of herbal extract THI on exercising healthy overweight humans: a randomized double-blind, placebo-controlled trial | |
| CN104352633B (en) | A kind of preparation method of pharmaceutical composition that treating osteoarthropathy | |
| CN103705812B (en) | A kind of pharmaceutical composition for the treatment of gout and its production and use | |
| CN104127514B (en) | A kind of Chinese medicine compound prescription treating obesity | |
| CN110507759A (en) | A kind of three yellow Chinese herbal preparation of particles and preparation method thereof with control hyperglycemia | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN1435247A (en) | Chinese medicine preparation for treating lithiasis in urinary system and urethral infection, and preparing method thereof | |
| CN101129710A (en) | Natural medicament for treating metabolism complex and method of preparing the same | |
| CN101647855B (en) | Traditional Chinese medicine preparation for treating diabetic neuropathy and preparation method thereof | |
| Park et al. | Dangnyohwan improves glucose utilization and reduces insulin resistance by increasing the adipocyte-specific GLUT4 expression in Otsuka Long-Evans Tokushima Fatty rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |